![]() |
市場調査レポート
商品コード
1624391
医薬品用膜ろ過市場:製品、技術、用途、地域別、2024年~2031年Pharmaceutical Membrane Filtration Market by Product, Technique (Microfiltration, Ultrafiltration, Nanofiltration, Reverse Osmosis, Ion Exchange), Application & Region for 2024-2031 |
||||||
|
医薬品用膜ろ過市場:製品、技術、用途、地域別、2024年~2031年 |
出版日: 2024年08月31日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2~3営業日
|
品質管理と製品の安全性への注目の高まりは、メーカーがより洗練されたろ過ソリューションを採用すると予測されることから、市場成長を促進する可能性が高いです。Verified Market Research社のアナリストによると、医薬品用膜ろ過市場は、2024年に約79億5,000万米ドルの評価額を下回り、2031年までに182億7,000万米ドルの評価額に達すると予測されています。
医薬品用膜ろ過市場の急拡大は、規制要件の厳格化により拡大が見込まれる高純度医薬品の需要増が主因です。これにより、市場は2024年から2031年にかけてCAGR 12.10%で成長します。
医薬品用膜ろ過市場定義/概要
医薬品用膜ろ過は、医薬品の生産と処理に利用される重要な技術です。液体から粒子を分離するために半透膜を使用する分離技術として定義され、このプロセスは医薬溶液の純度と安全性を確保するために採用されます。膜ろ過は、薬液の透明化、不純物の除去、有効成分の濃縮など、医薬品製造の複数の段階で一般的に利用されています。
医薬品用膜ろ過は、膜技術の進歩や、より高い製品の品質と安全性に対する規制上の要求の高まりにより、大きく拡大すると予想されています。さらに、個別化医療や生物製剤への注目の高まりは、高度なろ過ソリューションへの需要を促進し、製薬業界におけるこの必須技術の進化をさらに推進すると予想されます。
医薬品と生物製剤の需要の高まりにより、高品質の医薬品製造が重視されるようになっています。医薬品製造に関する規制基準の強化が実施されており、製品の純度と安全性を確保するために高度なろ過技術の採用が必要となっています。
慢性疾患の蔓延と世界のヘルスケア・インフラの拡大は、効率的なろ過システムの需要をさらに押し上げると予想されます。より効果的で耐久性のある材料の開発を含む膜ろ過の技術的進歩は、製薬業界の進化するニーズに対応するために導入されています。
さらに、医薬品製造を手がける受託製造会社の動向の高まりが、市場の拡大を後押しすると予想されます。廃棄物管理の改善と運転コストの低減を実現する膜ろ過技術の使用は、持続可能性と環境への影響の低減を重視する傾向が強まっていることも影響しています。
医薬品用膜ろ過市場における規制遵守とバリデーションがもたらす潜在的な影響は大きく、多面的です。規制遵守は、膜ろ過技術がFDAやEMAなどの保健当局が設定した厳しい基準を満たすことを保証すると予想されます。これらの基準は、ろ過システムの設計、製造、品質保証プロセスに影響を与える可能性が高いです。
これらのシステムの有効性と信頼性を検証するために予想されるバリデーション手順は、技術革新と技術開発を推進することにより、おそらく市場に影響を与えるであろう。メーカーは、バリデーション・プロセスがより厳しくなるにつれて、これらの変化する基準を満たすために、より高品質の材料やより精密なエンジニアリングに投資すると予想されます。これらの規制への準拠は、運用コストの増加をもたらすと予想されるが、製品の安全性と有効性の向上にもつながる可能性があります。
Enhanced focus on quality control and product safety is likely to propel market growth, as manufacturers are projected to adopt more sophisticated filtration solutions. According to the analyst from Verified Market Research, the Pharmaceutical Membrane Filtration Market is estimated to reach a valuation of USD 18.27 Billion By 2031 over the forecast subjugating around USD 7.95 Billion valued in 2024.
The rapid expansion of the pharmaceutical membrane filtration market is primarily driven by the increasing demand for high-purity pharmaceuticals, which is expected to escalate due to stricter regulatory requirements. It enables the market to grow at a CAGR of 12.10% from 2024 to 2031.
Pharmaceutical Membrane Filtration Market: Definition/ Overview
Pharmaceutical membrane filtration is a critical technology utilized in the production and processing of pharmaceutical products. Defined as a separation technique that uses a semi-permeable membrane to separate particles from liquids, this process is employed to ensure the purity and safety of pharmaceutical solutions. Membrane filtration is commonly utilized in multiple phases of pharmaceutical production, such as medication solution clarity, impurity removal, and active component concentration.
The pharmaceutical membrane filtration is anticipated to expand significantly, driven by advancements in membrane technology and increasing regulatory demands for higher product quality and safety. Additionally, the growing focus on personalized medicine and biologics is expected to fuel the demand for advanced filtration solutions, further propelling the evolution of this essential technology in the pharmaceutical industry.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Increasing emphasis on high-quality drug production is being driven by the rising demand for pharmaceuticals and biologics. Enhanced regulatory standards for pharmaceutical manufacturing are being implemented, necessitating the adoption of advanced filtration technologies to ensure product purity and safety.
The growing prevalence of chronic diseases and the expansion of the global healthcare infrastructure are expected to further boost the demand for efficient filtration systems. Technological advancements in membrane filtration, including the development of more effective and durable materials, are being introduced to meet the evolving needs of the pharmaceutical industry.
Furthermore, it is anticipated that the growing trend of contract manufacturing companies handling pharmaceutical manufacturing will support market expansion. The use of membrane filtering technologies, which provide improved waste management and lower operating costs, is also influenced by the growing emphasis on sustainability and reducing environmental effects.
The potential impacts of regulatory compliance and validation on the pharmaceutical membrane filtration market are substantial and multifaceted. Regulatory compliance is anticipated to ensure that membrane filtration technologies meet stringent standards set by health authorities such as the FDA and EMA. These standards are likely to affect the design, manufacturing, and quality assurance processes of filtration systems.
Validation procedures, which are anticipated to verify the effectiveness and dependability of these systems, would probably have an impact on the market by propelling innovations and technical developments. Manufacturers are expected to invest in higher-quality materials and more precise engineering to fulfil these changing criteria as validation processes become more stringent. Compliance with these regulations is expected to increase operational costs, but it may also result in enhanced product safety and effectiveness.
According to VMR analysis, the demand for nanofiltration is largely propelled by the growing emphasis on the purification and concentration of pharmaceutical products. Thus, the high demand by pharmaceutical industries is enabling the nanofiltration segment to hold a major share in the market. This technology is highly valued for its ability to selectively remove contaminants while retaining valuable solutes, which is essential in ensuring the purity and efficacy of pharmaceutical formulations. The heightened focus on drug safety and quality control has led to the implementation of stricter regulatory standards, thereby necessitating advanced filtration technologies like NF to meet these requirements.
The use of nanofiltration is also being fueled by the growing complexity of pharmaceutical formulations, which includes the requirement to handle synthetic pharmaceuticals and high-value biologics. This technique is favored because it can precisely achieve high-performance separation while managing a variety of feed streams. The need for cutting-edge filtration technologies to guarantee the quality and safety of these breakthroughs is anticipated to increase as new drug discoveries and formulations are made.
The rapid growth of cell separation within the pharmaceutical membrane filtration market is anticipated to be driven by the rising prevalence of chronic diseases is expected to lead to an increase in demand for advanced therapeutic solutions, thereby propelling the need for effective cell separation technologies. Moreover, the expansion of biopharmaceuticals and personalized medicine is projected to boost the adoption of membrane filtration systems, as these technologies are integral to the production of high-purity biologics and the development of personalized therapies. Technological advancements in membrane materials and filtration processes are also likely to enhance the efficiency and performance of cell separation techniques, further stimulating market growth.
Additionally, increasing investments in research and development by pharmaceutical companies and research institutions are expected to foster innovation and drive the evolution of cell separation technologies. Regulatory support and the growing emphasis on stringent quality control standards in pharmaceutical manufacturing are anticipated to contribute to the market's expansion, as advanced filtration solutions are required to meet these high standards.
According to VMR analyst, the North American market for pharmaceutical membrane filtration is anticipated to dominate in the coming years. The market is projected to be driven by a combination of factors including increased pharmaceutical production, heightened demand for advanced filtration technologies, and stringent regulatory standards governing drug manufacturing.
Investments in research and development by major pharmaceutical companies in the region are expected to contribute to the development of innovative membrane filtration solutions, further supporting market expansion. Additionally, the rising prevalence of chronic diseases and the growing focus on improving drug safety and efficacy are likely to augment the demand for advanced filtration systems in North America.
The pharmaceutical membrane filtration market in Asia Pacific is estimated to witness rapid growth due to the benefits of a burgeoning pharmaceutical industry, driven by increasing investments in healthcare infrastructure and the rising demand for high-quality pharmaceuticals.
The expansion of pharmaceutical manufacturing facilities and the growing emphasis on adhering to international quality standards are expected to fuel the need for advanced membrane filtration technologies. Additionally, the increasing adoption of biopharmaceuticals and biosimilars in the region is likely to drive demand for effective filtration solutions, positioning Asia Pacific as a rapidly growing market for pharmaceutical membrane filtration.
The Pharmaceutical Membrane Filtration Market's competitive landscape is characterized by a varied range of companies, including technology developers, plant operators, and service providers, all striving for market share in an increasingly dynamic and growing industry.
Some of the prominent players operating in the pharmaceutical membrane filtration market include:
Merck KGaA
Danaher Corporation
Sartorius Stedim Biotech
3M Company
Thermo Fisher Scientific, Inc.
Parker-Hannifin Corporation
GE Healthcare
GEA Group
Pall Corporation
Koch Membrane Systems
In November 2023, Repligen Corporation launched a self-contained tangential flow filtration device. It is a significant advancement in flat sheet TFF technology for ultrafiltration and diafiltration.
In October 2023, Cytiva inaugurated a new manufacturing facility in Pune, India. It specializes in bioprocessing equipment, including tangential flow filtration systems, virus filtration systems, and virus inactivation systems.